MARKET

GBT

GBT

Global Blood
NASDAQ
67.75
-0.24
-0.35%
After Hours: 67.77 +0.02 +0.03% 17:08 09/26 EDT
OPEN
67.92
PREV CLOSE
67.99
HIGH
68.13
LOW
67.74
VOLUME
1.75M
TURNOVER
0
52 WEEK HIGH
73.02
52 WEEK LOW
21.65
MARKET CAP
4.57B
P/E (TTM)
-13.5533
1D
5D
1M
3M
1Y
5Y
Pfizer to further tap CytoReason's AI technology for drug discovery in up to $110M deal
Pfizer (NYSE:<a href="https://seekingalpha.com/symbol/PFE?utm_medium=referral&utm_source=webull.com" title="Pfizer Inc." target="...
Seekingalpha · 6d ago
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease PatientsSOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ...
GlobeNewswire · 09/15 22:00
Global Blood Therapeutics's Return On Capital Employed Overview
Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q2 sales of $71.55 million. Earnings fell to a loss of $82.47 million, resulting in a 1.29% decrease from last quarter.
Benzinga · 09/15 14:10
GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference
Keynote by Admiral Rachel Levine, M.D., Assistant Secretary for Health, U.S. Department of Health and Human ServicesSOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Si...
GlobeNewswire · 09/08 12:00
Global Blood (GBT) Up 1.9% Since Last Earnings Report: Can It Continue?
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/07 15:30
Insider Sell: Global Blood Therapeutics
Insider Sell: Global Blood Therapeutics
MT Newswires · 09/07 08:19
M&A may be a tailwind for biotech sector into end of year, analyst says
Mergers and acquisitions could be a "tailwind" into the end of the year, especially after recent announced deals by Pfizer Inc. (NYSE:<a href="https://seekingalpha.com/symbol/PFE?utm_medium=referral&utm_source=w...
Seekingalpha · 09/04 13:18
After Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics Deal
Benzinga · 09/01 13:55
More
About GBT
Global Blood Therapeutics, Inc. is a biopharmaceutical company that discovers, develops and delivers treatments. The Company is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). It is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company’s next-generation HbS polymerization inhibitor. The Company is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.

Webull offers kinds of Global Blood Therapeutics Inc stock information, including NASDAQ:GBT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GBT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GBT stock methods without spending real money on the virtual paper trading platform.